Fast Track Designation

An FDA process designed to facilitate the development and expedite the review of drugs to treat serious conditions and fill unmet medical needs.

Fast Track Designation is a formal program administered by the U.S. Food and Drug Administration (FDA) to accelerate the development and expedite the review of new drugs and vaccines. To qualify, a drug candidate must be intended to treat a serious medical condition and demonstrate the potential to address an unmet medical need. This status is typically requested by the sponsoring pharmaceutical or biotechnology company during the investigational clinical trial phases. Once granted, the designation provides the drug sponsor with several key operational advantages. These include more frequent meetings and written communications with the FDA to discuss study design and data collection. It also grants eligibility for Priority Review, which shortens the FDA's review goal from ten months to six months, and Rolling Review, which allows the company to submit completed sections of its New Drug Application (NDA) or Biologics License Application (BLA) individually rather than waiting for the entire application to be finished. For biotechnology and pharmaceutical investors, Fast Track Designation is a highly watched regulatory milestone. It can significantly reduce the time and capital required to bring a therapeutic candidate to market, thereby improving the projected net present value of a company's pipeline. However, investors must be cautious; the designation is not an endorsement of the drug's safety or efficacy, nor does it guarantee final regulatory approval or clinical trial success. It simply represents an administrative commitment by the FDA to expedite the evaluation process.

A clinical-stage biotech company is developing a novel oncology drug. Under standard review, the company would have to wait until its entire 1,200-page Biologics License Application (BLA) is complete before submitting it, followed by a standard 10-month FDA review period. After receiving Fast Track Designation, the company submits its preclinical data in Month 1, clinical safety data in Month 3, and final manufacturing data in Month 5 under a rolling review. The FDA begins reviewing each section immediately upon receipt, and grants a Priority Review of 6 months instead of 10. This cuts the total regulatory review timeline down from 10 months post-final submission to just 6 months, saving the company 4 months of operational cash burn.